Bonesupport Holding AB - Asset Resilience Ratio

Latest as of September 2025: 37.71%

Bonesupport Holding AB (BONEX) has an Asset Resilience Ratio of 37.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BONEX current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr379.02 Million
≈ $40.79 Million USD Cash + Short-term Investments

Total Assets

Skr1.01 Billion
≈ $108.17 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Bonesupport Holding AB's Asset Resilience Ratio has changed over time. See Bonesupport Holding AB net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Bonesupport Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Bonesupport Holding AB.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr379.02 Million 37.71%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr379.02 Million 37.71%

Asset Resilience Insights

  • Very High Liquidity: Bonesupport Holding AB maintains exceptional liquid asset reserves at 37.71% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Bonesupport Holding AB Industry Peers by Asset Resilience Ratio

Compare Bonesupport Holding AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Alcon AG
SW:ALC
Medical Instruments & Supplies 0.26%
iRay Technology Co Ltd
SHG:688301
Medical Instruments & Supplies 0.68%
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Medical Instruments & Supplies 29.19%
Jiangsu Nanfang Medical
SHG:603880
Medical Instruments & Supplies 2.27%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 6.36%
I.Ceram SA
PA:ALICR
Medical Instruments & Supplies -1.61%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 4.42%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 51.82%

Annual Asset Resilience Ratio for Bonesupport Holding AB (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Bonesupport Holding AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 25.80% Skr227.00 Million
≈ $24.43 Million
Skr879.69 Million
≈ $94.67 Million
+1.51pp
2023-12-31 24.30% Skr167.35 Million
≈ $18.01 Million
Skr688.82 Million
≈ $74.13 Million
-29.84pp
2022-12-31 54.13% Skr201.28 Million
≈ $21.66 Million
Skr371.82 Million
≈ $40.01 Million
-5.90pp
2021-12-31 60.03% Skr206.46 Million
≈ $22.22 Million
Skr343.92 Million
≈ $37.01 Million
-16.00pp
2020-12-31 76.04% Skr353.74 Million
≈ $38.07 Million
Skr465.22 Million
≈ $50.06 Million
+29.14pp
2019-12-31 46.89% Skr92.06 Million
≈ $9.91 Million
Skr196.33 Million
≈ $21.13 Million
-33.28pp
2018-12-31 80.17% Skr261.47 Million
≈ $28.14 Million
Skr326.14 Million
≈ $35.10 Million
-9.22pp
2017-12-31 89.39% Skr533.37 Million
≈ $57.40 Million
Skr596.68 Million
≈ $64.21 Million
+14.44pp
2016-12-31 74.94% Skr141.50 Million
≈ $15.23 Million
Skr188.81 Million
≈ $20.32 Million
--
pp = percentage points

About Bonesupport Holding AB

ST:BONEX Sweden Medical Instruments & Supplies
Market Cap
$1.56 Billion
Skr14.53 Billion SEK
Market Cap Rank
#7220 Global
#101 in Sweden
Share Price
Skr220.60
Change (1 day)
+3.86%
52-Week Range
Skr167.90 - Skr340.00
All Time High
Skr400.20
About

Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin duri… Read more